| Dr Michael G Goodman, MD | |
|
107 6th Ave Sw, Ronan, MT 59864 | |
| (406) 676-4441 | |
| (406) 676-0835 |
| Full Name | Dr Michael G Goodman |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Medical Oncology |
| Location | 107 6th Ave Sw, Ronan, Montana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427034834 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RX0202X | Internal Medicine - Medical Oncology | 8025 (Montana) | Primary |
| 174400000X | Specialist | 8025 (Montana) | Secondary |
| Entity Name | St Lukes Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306911169 PECOS PAC ID: 5496659567 Enrollment ID: O20031121000276 |
News Archive
Scientists report that they have a better understanding of the complex effects of radiation on tumor biology and that specific radiation treatment regimens may enhance the effectiveness of radiotherapy, even in tumor populations that have been notoriously difficult to treat.
More than half of the 236 million people who have been diagnosed with COVID-19 worldwide since December 2019 will experience post-COVID symptoms -; more commonly known as "long COVID" -; up to six months after recovering, according to Penn State College of Medicine researchers.
In a new pre-clinical study published this week in the journal Leukemia, the research team of Children's Hospital Los Angeles investigator Hisham Abdel-Azim, MD, MS, worked with colleagues to engineer T-cells to identify and target multiple sites on acute lymphoblastic leukemia cells instead of just one. The early collaboration points the way to future clinical trials to test the therapy.
Drugs aimed at suppressing inflammation-provoking cytokines-specifically those linked to T-cells-have improved the treatment of rheumatoid arthritis (RA), a chronic, inflammatory autoimmune disease. Still, the frequency of remission achieved by these biologic agents remains below 50 percent.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael G Goodman, MD 107 6th Ave Sw, Ronan, MT 59864-2634 Ph: (406) 676-4441 | Dr Michael G Goodman, MD 107 6th Ave Sw, Ronan, MT 59864 Ph: (406) 676-4441 |
News Archive
Scientists report that they have a better understanding of the complex effects of radiation on tumor biology and that specific radiation treatment regimens may enhance the effectiveness of radiotherapy, even in tumor populations that have been notoriously difficult to treat.
More than half of the 236 million people who have been diagnosed with COVID-19 worldwide since December 2019 will experience post-COVID symptoms -; more commonly known as "long COVID" -; up to six months after recovering, according to Penn State College of Medicine researchers.
In a new pre-clinical study published this week in the journal Leukemia, the research team of Children's Hospital Los Angeles investigator Hisham Abdel-Azim, MD, MS, worked with colleagues to engineer T-cells to identify and target multiple sites on acute lymphoblastic leukemia cells instead of just one. The early collaboration points the way to future clinical trials to test the therapy.
Drugs aimed at suppressing inflammation-provoking cytokines-specifically those linked to T-cells-have improved the treatment of rheumatoid arthritis (RA), a chronic, inflammatory autoimmune disease. Still, the frequency of remission achieved by these biologic agents remains below 50 percent.
› Verified 5 days ago